19 June 2013
Keywords: repligen, uridine, prodrug, bipolar, disorder, initiated, phase
Article | 27 January 2003
Repligen has initiated a Phase I/II clinical trial of RG2133, a prodrugof uridine, in patients with either bipolar disorder ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 January 2003
18 June 2013
© 2013 thepharmaletter.com